期刊文献+

前列地尔与肾康中西医结合治疗对慢性肾功能衰竭患者肾功能及血脂的影响 被引量:12

Efficacy of alprostadil and Shenkang on regulating renal function and lipids in patients with chronic renal failure
原文传递
导出
摘要 目的 探讨前列地尔和肾康联合对调整慢性肾功能衰竭(CRF)患者肾功能和血脂水平的效果.方法 选择98例CRF患者为研究对象,采用1:1随机对照双盲实验的分组原则分为研究组与对照组(各49例),两组给予优质低蛋白、低脂低盐饮食、控制感染、利尿消肿,纠正酸中毒、降压、纠正电解质平衡失调等常规治疗,治疗组在常规治疗的基础上应用前列地尔注射液20 μg+ 100 ml生理盐水,静脉滴注1次/d;肾康注射液100 ml+ 5%葡萄糖溶液300 ml,静脉滴注1次/d.对照组在常规治疗的基础上加用川芎嗪200 mg+5%葡萄糖注射液250 ml,静脉滴注1次/d.两组疗程均为14 d.比较两组治疗前后肾功能、脂代谢、药物不良反应等.结果 治疗前两组肾功能差异无统计学意义(P均>0.05),治疗后研究组与对照组血肌酐[(313.7±66.2)、(358.4±53.9) μmol/L]、尿素氮[(15.3±2.9)、(18.4±3.0) mmol/L]、24h尿蛋白[(1.24±0.45)、(1.57±0.39) g/24 h]、内生肌酐清除率(Ccr)[(35.7±5.4)、(28.4±4.3) mmol/L]差异均有统计学意义(t值分别为3.754、7.864、5.873、7.864,P均<0.05).治疗前两组血脂差异无统计学意义(P均>0.05),治疗后研究组与对照组甘油三酯[(2.12±1.26)、(2.32±1.34) mmol/L]、总胆固醇[(4.91±1.43)、(5.35±1.31) mmol/L]、高密度脂蛋白胆固醇[(1.39±0.43)、(1.23±0.37) mmol/L]、低密度脂蛋白胆固醇[(2.39±0.68)、(2.73±0.88)mmol/L]差异均有统计学意义(t值分别为3.876、4.661、5.387、8.543,P均<0.05).两组治疗过程均无药物不良反应产生.结论 前列地尔、肾康注射液联合可显著改善患者的肾功能、脂代谢紊乱等,未发现明显的不良反应,值得临床广泛应用. Objective To investigate efficacy in Alpmstadil and Shenkang on regulating renal function and lipids in patients with chronic renal failure (CRF).Methods Ninety-eight cases of CRF patients were collected for the study,and 1:1 randomized,double-blind experiment grouping principles were used in the current study.All cases were divided into study group and the control group (49 cases of each group).The two group were given the high quality low protein,low fat low salt diet,inftion control,diuretic swelling,correct acidosis,buck,correction of electrolyte imbalance and other conventional treatment.The patients in study group on the basis of conventional therapy were given 20 g Alprostadil injection + 100 ml saline,intravenous infusion of 1times/d,and 100 ml Shenkang injection +300 ml 5% glucose the solution,intravenous infusion of 1 times/d.While patients of control grrup on the basis of conventional therapy plus 200 mg Ligustrazine + 250 ml 5%Glucose Injection,intravenous infusion of 1times/d.Two groups were treated for 14 d.Before and after treatment,renal function,lipid metabolism,adverse drug reactions were observed and determined.Results There was no significant difference in term of renal function between two groups before treatment(P 〉 0.05).After treatment,the levels of serum creatinine,blood urea nitrogen,24 h-Urine protein and creatinine clearance(Ccr) in study group were (313.7 ±66.2) mmol/L,(15.3 ±2.9) mmol/L,(1.24 ±0.45) g/24 h and (35.7 ±5.4) mmol/L respectively,significant different from those in control group ((358.4 ± 53.9) mmol/L,(18.4 ± 3.0) mmol/L,(1.57 ±0.39) g/24 h and (28.4 ±4.3) mmol/L;t =3.754,7.864,5.873,4.312,P 〈0.05).There was no significant difference in term of blood fat between two groups before treatment (P 〉 0.05).In study group,the levels of glycerin trilaurate,cholesterol total,high density hpoprotein cholesterol,low density lipoprotein cholesterol were significantly different than those in the control grou
作者 邵敏 胡永玮
出处 《中国综合临床》 2014年第12期1303-1306,共4页 Clinical Medicine of China
关键词 慢性肾功能衰竭 前列地尔 肾康 Chronic renal failure Alprostadil Shenkang
  • 相关文献

参考文献5

二级参考文献62

  • 1吴晨光,王丽,方春钱,高静.还原型谷胱甘肽对糖尿病大鼠肾脏保护作用的机制研究[J].中华糖尿病杂志,2009,1(5). 被引量:8
  • 2傅鹏,于光,黄雪强,许静,梅小斌,吴灏,袁伟杰.中西医结合疗法延缓慢性肾功能不全患者急性肾功能减退的临床研究[J].中西医结合学报,2004,2(6):429-431. 被引量:8
  • 3沈庆法.中医临床肾脏病学[M].上海:上海科技文献出版社,1998.452-453. 被引量:15
  • 4National Kidney Foundation.K/DOQI clinical practice guidelines for chronic kidney disease:evaluation,classification,and stratification.Am J Kidney Dis,2002,39(2 Suppl 1):S1-266. 被引量:1
  • 5Levey AS,Eckardt KU,Tsukamoto Y,et al.Definition and classification of chronic kidney disease:a position statement from Kidney Disease:Improving Global Outcomes (KDIGO).Kidney Int,2005,67:2089-2100. 被引量:1
  • 6Meguid EI,Nahas A,Bello AK.Chronic kidney disease:the global challenge.Lancet,2005,365:331-340. 被引量:1
  • 7Couser WG.Chronic kidney disease the promise and the perils.J Am Soc Nephrol,2007,18:2803-2805. 被引量:1
  • 8Hallan SI,Ritz E,Lydersen S,et al.Combining GFR and albuminuria to classify CKID improves prediction of ESRD.J Am Soc Nephrol,2009,20:1069-1077. 被引量:1
  • 9Zhang L,Zhang P,Wang F,et al.Prevalence and factors associated with CKD:a population study from Beijing.Am J Kidney Dis,2008,51:373-384. 被引量:1
  • 10Wen CP,Cheng TY,Tsai MK,et al.All-cause mortality attributable to chronic kidney disease:a prospective cohort study based on 462 293 adults in Taiwan.Lancet,2008,371:2173-2182. 被引量:1

共引文献93

同被引文献89

引证文献12

二级引证文献80

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部